Skip to main content
. 2016 Mar 1;17(3):316. doi: 10.3390/ijms17030316

Figure 6.

Figure 6

Effect of EGCg-AuNPs and free EGCg on endothelial and smooth muscles cells viability; (means ± SE; n = 3), cells treated for 24 h. (A) HUVECs (Human umbilical vein endothelial cells): * p < 0.05 vs. EGCg-AuNPs at same concentration (40 µg/mL); (B) HCASMCs (Human coronary artery smooth muscle cells): * p > 0.05 vs. EGCg-AuNPs at same concentration (40 µg/mL).